11/10
12:06 pm
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.
11/8
07:05 pm
iron
What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]
Low
Report
What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]
11/6
08:30 am
iron
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
09:00 am
iron
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Low
Report
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
11/3
08:03 am
iron
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.
10/31
08:30 am
iron
Disc Medicine to Participate in Upcoming Investor Conferences
Low
Report
Disc Medicine to Participate in Upcoming Investor Conferences
10/30
02:19 pm
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Morgan Stanley from $90.00 to $115.00. They now have an "overweight" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Morgan Stanley from $90.00 to $115.00. They now have an "overweight" rating on the stock.
10/21
12:14 am
iron
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
10/20
07:00 am
iron
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
10/20
06:30 am
iron
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
Low
Report
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
10/18
09:34 pm
iron
Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval [Yahoo! Finance]
Medium
Report
Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval [Yahoo! Finance]
10/17
11:00 am
iron
Disc Medicine (NASDAQ:IRON) was given a new $153.00 price target on by analysts at National Bankshares, Inc..
Low
Report
Disc Medicine (NASDAQ:IRON) was given a new $153.00 price target on by analysts at National Bankshares, Inc..
10/17
10:47 am
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Cantor Fitzgerald from $132.00 to $153.00. They now have an "overweight" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Cantor Fitzgerald from $132.00 to $153.00. They now have an "overweight" rating on the stock.
10/17
10:03 am
iron
Disc Medicine (NASDAQ:IRON) was given a new $108.00 price target on by analysts at Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) was given a new $108.00 price target on by analysts at Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.
10/17
09:00 am
iron
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
Medium
Report
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
10/17
08:35 am
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Wedbush from $90.00 to $110.00. They now have an "outperform" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Wedbush from $90.00 to $110.00. They now have an "outperform" rating on the stock.
10/16
07:27 pm
iron
Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) [Yahoo! Finance]
Medium
Report
Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) [Yahoo! Finance]
10/16
05:35 pm
iron
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
Low
Report
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
10/2
12:13 pm
iron
A Fresh Look at Disc Medicine's Valuation After Bitopertin NDA Submission and Positive Phase 2 Data [Yahoo! Finance]
Low
Report
A Fresh Look at Disc Medicine's Valuation After Bitopertin NDA Submission and Positive Phase 2 Data [Yahoo! Finance]
9/30
08:30 am
iron
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Low
Report
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)